Purchase Order N4034522P0126

The U.S. Department of the Navy awarded a $247,371.53 firm-fixed-price purchase order contract to Praesensbio LLC, a for-profit limited liability company, for a "Sequence Based Detection Biothreat Agent" requirement. The contract has a period of performance through March 29, 2024 and was awarded on September 27, 2023 without a set-aside. The requirement was originally solicited as an 8(a) sole source opportunity. Based on the description, this contract appears to support the Department...

This federal contract was awarded by the Department of the Navy Bureau of Medicine and Surgery to Biomedic Science Material Joint Stock Company (Biomedic., Jsc), a for-profit and DOT-certified Disadvantaged Business Enterprise (DBE) organization. The $342,783.26 Firm Fixed Price purchase order is for DNA sequencing machines, with a completion date of November 30, 2021. The contract is associated with the National Interest Action Code for the Coronavirus COVID-19 pandemic and the Department of...

This federal contract award was made by the Bureau of Medicine and Surgery, a component of the U.S. Department of the Navy, to Pathoseq Bio, LLC, a small business limited liability company. The $155,106.15 firm-fixed-price contract is for genomic analysis services, with a period of performance through March 31, 2025. The contract was set aside for total small business participation. Pathoseq Bio specializes in advanced biological research, genomic analysis, and biothreat detection for federal...

<p>This is a firm fixed-price purchase order contract awarded by the U.S. Department of the Navy's Bureau of Medicine and Surgery to Institut Pasteur DU Laos for $67,109.20 to provide sequence-based detection services. The contract has an ultimate completion date of September 14, 2025. There is no set-aside designation for this award.</p>

The Department of the Navy Bureau of Medicine and Surgery awarded a $634,200 firm fixed price delivery order to Gen-Probe Incorporated Gen-Probe Sales &amp; Service, Inc. Division for the APTIMA SARS-COV-2 ASSAY. This contract was awarded under the National Interest Action Code for Coronavirus COVID-19 and will provide the assay, which tests for the virus that causes COVID-19, for use by the Navy. Performance will take place in San Diego, California over a one week period concluding on July...

The Department of the Navy Bureau of Medicine and Surgery awarded a $9,275 purchase order to Miscellaneous Foreign Awardees - doing business as Federal Egov IAE Initiative - Generic Entity Identifier for D4085: SELECT-A-SIZE DNA CLEAN &amp; CONCENT. The contract has a period of performance from June 28, 2023 through September 29, 2023 to be carried out in Peru on a firm fixed price basis. The Bureau of Medicine and Surgery supports the Navy and Marine Corps through the provision of healthcare...

The Department of the Navy Bureau of Medicine and Surgery awarded a firm fixed-price purchase order to Quanterix Corporation, a for-profit life sciences company, for a QUANTERIX SP - X IMAGING ANALYSIS SYSTEM valued at $147,321.00. This award, which does not have a set-aside designation, supports the agency's efforts related to the COVID-19 national interest action. Quanterix has received over $30 million in prior federal contracts from agencies including the NIH, VA, and DoD to supply its Simoa...

This is a firm fixed price purchase order awarded by the Chief of Naval Operations (CNO), a Defense agency, to Bio-Active Company LIMITED, a for-profit limited liability company. The contract is to provide Illumina sequencing systems, reagents, and testing materials to support infectious disease monitoring and research conducted by the U.S. government in Thailand. The total ceiling value of the purchase order is $35,043.75, and the period of performance runs through May 2, 2023. This award...

The Department of the Navy Bureau of Medicine and Surgery awarded a $175,995.80 firm fixed price purchase order to Life Technologies Corporation for the delivery of COVID-19 testing kits and related laboratory supplies. The products to be provided under the contract include TaqPath RT-PCR COVID-19 test kits, MagMAX Proteinase K enzyme preparation kits, and other molecular diagnostics reagents. Performance will take place in Silver Spring, Maryland through January 2024. As the parent company,...

This $77,750 firm-fixed-price purchase order was awarded by the U.S. Army Medical Research Acquisition Activity (USAMRAA) to Pacific Biosciences of California, Inc., a small business manufacturer of specialized scientific equipment and consumables. The contract provides Pacific Biosciences' Sequel and Sequel II DNA/RNA sequencing systems, along with associated reagents and supplies, to support genomic research initiatives across the Department of Defense and other federal agencies. The award...